Health
FDA Authorizes Marketing of Device to Improve Gait in Multiple Sclerosis Patients – FDA.gov
FDA has authorized marketing of a new device intended for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis
For Immediate Release:
March 26, 2021
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. The device, called Portable Neuromodulation Stimulator (PoNS), is a neuromuscular tongue stimulator that…
-
General19 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
Noosa News22 hours agoSanta drops in for carols
-
Business23 hours agoHow much upside does Macquarie predict for Sonic Healthcare shares?
-
General20 hours agoTwo dead after separate road accidents in regional New South Wales